2-Methoxyestradiol
From Wikipedia, the free encyclopedia
 |
|
|
2-Methoxyestradiol
|
|
| Systematic (IUPAC) name | |
| (8R,9S,13S,14S,17S)-2-methoxy- 13-methyl-6,7,8,9,11,12,14,15,16,17- decahydrocyclopenta[a]phenanthrene-3,17-diol |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H26O3 |
| Mol. mass | 302.408 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It is derived from estrogen, although it binds poorly to known estrogen receptors, and belongs to the family of drugs called angiogenesis inhibitors. It has undergone Phase 1 clinical trials against breast cancers. Preclinical models also suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis. The CAS name for 2ME2 is (17 beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diol. It also acts as a vasodilator.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
